Anti-Mouse TNFα-141Pr

Catalog: 3141013B

Clone: MP6-XT22

Isotype: IgG1

Package Size: 100 tests

Storage: Store product at 4°C. Do not freeze.

Formulation: Antibody stabilizer with 0.05% Sodium Azide

Technical Information

Validation: Each lot of conjugated antibody is quality control tested by CyTOF® analysis of stained cells using the appropriate positive and negative cell staining and/or activation controls.

Recommended Usage: The suggested use is 1 µl for up to 3 x 10^6 live cells in 100 µl. It is recommended that the antibody be titrated for optimal performance for each of the desired applications.

Description

Tumor Necrosis Factor (TNF) alpha, also known as cachexin, is a cytokine with a primary role of regulation of immune cells. It plays a role in the acute inflammatory response to infections and has cytolytic activity against tumor cells. It is produced primarily by activated macrophages but can be produced in other cells such as activated monocytes and T cells.

References


For technical support visit fluidigm.com/support

EMAIL
United States support.northamerica@fluidigm.com | Europe support.europe@fluidigm.com
Asia techsupportasia@fluidigm.com | Latin America techsupportlatam@fluidigm.com
All other countries techsupport@fluidigm.com

PHONE
United States (toll-free) +1 866 358 4354 | Europe +33 1 60 92 42 40
Japan +81 3 3662 2150 | China (excluding Hong Kong) +86 21 3255 8368
All other countries +1 650 266 6100

For Research Use Only. Not for use in diagnostic procedures.

This product contains antibodies manufactured by and sold under license from BioLegend and licensees thereof. Information in this publication is subject to change without notice. Safety data sheet information fluidigm.com/sds Patent and license information fluidigm.com/legalnotices | Fluidigm, the Fluidigm logo, Cell-ID, CyTOF, and Maxpar are trademarks or registered trademarks of Fluidigm Corporation in the United States and/or other countries. All other trademarks are the sole property of their respective owners. © 2015 Fluidigm Corporation. All rights reserved. 06/2015